JP7101171B2 - Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 - Google Patents

Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 Download PDF

Info

Publication number
JP7101171B2
JP7101171B2 JP2019517909A JP2019517909A JP7101171B2 JP 7101171 B2 JP7101171 B2 JP 7101171B2 JP 2019517909 A JP2019517909 A JP 2019517909A JP 2019517909 A JP2019517909 A JP 2019517909A JP 7101171 B2 JP7101171 B2 JP 7101171B2
Authority
JP
Japan
Prior art keywords
indicates
alkyl
cycloalkyl
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019517909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534255A (ja
Inventor
ウー，トンフェイ
ブレーマー，ダーク
ベケ，リッツ
ブークス，アン
スタニスラス マーセラ ディールス，ガストン
チャールズ ローソン，エドワード
ミールポエル，リーヴェン
パンデ，ヴィニート
コルネリス ベルナルデュス カタリナ パレード，マルクス
バート グリート スチェペンズ，ウィム
サン，ウェイメイ
ヴィルヘルムス ジョン エフ． チューリング，ヨハネス
ヴィエレヴォイ，マルセル
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Priority claimed from PCT/EP2017/074983 external-priority patent/WO2018065365A1/en
Publication of JP2019534255A publication Critical patent/JP2019534255A/ja
Priority to JP2022033419A priority Critical patent/JP7576587B2/ja
Application granted granted Critical
Publication of JP7101171B2 publication Critical patent/JP7101171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019517909A 2016-10-03 2017-10-02 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 Active JP7101171B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022033419A JP7576587B2 (ja) 2016-10-03 2022-03-04 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662403336P 2016-10-03 2016-10-03
US62/403,336 2016-10-03
EP17157785 2017-02-24
EP17157785.1 2017-02-24
PCT/EP2017/074983 WO2018065365A1 (en) 2016-10-03 2017-10-02 Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022033419A Division JP7576587B2 (ja) 2016-10-03 2022-03-04 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Publications (2)

Publication Number Publication Date
JP2019534255A JP2019534255A (ja) 2019-11-28
JP7101171B2 true JP7101171B2 (ja) 2022-07-14

Family

ID=60043171

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019517909A Active JP7101171B2 (ja) 2016-10-03 2017-10-02 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
JP2022033419A Active JP7576587B2 (ja) 2016-10-03 2022-03-04 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022033419A Active JP7576587B2 (ja) 2016-10-03 2022-03-04 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Country Status (15)

Country Link
US (3) US11098062B2 (https=)
EP (1) EP3519413A1 (https=)
JP (2) JP7101171B2 (https=)
KR (1) KR102531344B1 (https=)
CN (2) CN115626935B (https=)
AU (1) AU2017338269B2 (https=)
BR (1) BR112019006414A2 (https=)
CA (1) CA3037998A1 (https=)
IL (1) IL265718B (https=)
MA (1) MA46341A (https=)
MX (2) MX2019003843A (https=)
PE (1) PE20190706A1 (https=)
PH (1) PH12019500731A1 (https=)
TN (1) TN2019000087A1 (https=)
UA (1) UA124074C2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022084699A (ja) * 2016-10-03 2022-06-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
IL275129B2 (en) 2017-12-08 2023-10-01 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
WO2019219805A1 (en) * 2018-05-16 2019-11-21 Ctxone Pty Ltd Combination therapy
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
WO2021055797A1 (en) * 2019-09-18 2021-03-25 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20230066014A1 (en) * 2019-12-03 2023-03-02 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
CN113186153B (zh) * 2021-04-15 2023-09-08 南方医科大学 Prmt5抑制剂在促进精原干细胞损伤再生和增殖中的应用
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501694A (ja) 1995-06-07 2000-02-15 アボツト・ラボラトリーズ 複素環置換シクロペンタン化合物
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016135582A1 (en) 2015-02-24 2016-09-01 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
WO2003070739A1 (en) 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20060167241A1 (en) 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
AU2010330823A1 (en) 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
US9284343B2 (en) 2011-04-04 2016-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
JP2014530910A (ja) 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 新規化合物
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
PE20181894A1 (es) 2016-03-10 2018-12-11 Janssen Pharmaceutica Nv Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5
CN115626935B (zh) 2016-10-03 2025-07-15 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
IL275129B2 (en) 2017-12-08 2023-10-01 Janssen Pharmaceutica Nv Novel spirobicyclic analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501694A (ja) 1995-06-07 2000-02-15 アボツト・ラボラトリーズ 複素環置換シクロペンタン化合物
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016135582A1 (en) 2015-02-24 2016-09-01 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022084699A (ja) * 2016-10-03 2022-06-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
JP7576587B2 (ja) 2016-10-03 2024-10-31 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体

Also Published As

Publication number Publication date
JP7576587B2 (ja) 2024-10-31
KR102531344B1 (ko) 2023-05-10
CA3037998A1 (en) 2018-04-12
MX2023005574A (es) 2023-05-29
US20210371433A1 (en) 2021-12-02
US11993614B2 (en) 2024-05-28
MX2019003843A (es) 2019-06-24
US11098062B2 (en) 2021-08-24
IL265718B (en) 2021-08-31
BR112019006414A2 (pt) 2019-06-25
TN2019000087A1 (en) 2020-07-15
US20190263833A1 (en) 2019-08-29
CN109803971A (zh) 2019-05-24
JP2019534255A (ja) 2019-11-28
EP3519413A1 (en) 2019-08-07
UA124074C2 (uk) 2021-07-14
CN109803971B (zh) 2022-10-28
PH12019500731A1 (en) 2019-06-24
US20240124493A1 (en) 2024-04-18
JP2022084699A (ja) 2022-06-07
CN115626935B (zh) 2025-07-15
IL265718A (en) 2019-05-30
AU2017338269B2 (en) 2021-03-25
KR20190056425A (ko) 2019-05-24
MA46341A (fr) 2019-08-07
CN115626935A (zh) 2023-01-20
AU2017338269A1 (en) 2019-04-04
PE20190706A1 (es) 2019-05-17

Similar Documents

Publication Publication Date Title
JP7101171B2 (ja) Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
JP7720732B2 (ja) Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体
CN108884108B (zh) 用于用作prmt5抑制剂的取代核苷类似物
JP7352544B2 (ja) 新規なスピロ二環式類似体
WO2018065365A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
JP6909799B2 (ja) Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ
EA044355B1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
HK40033790B (en) Spirobicyclic analogues
HK40000429A (en) Substituted nucleoside analogues for use as prmt5 inhibitors
EA045894B1 (ru) Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5
HK40000429B (zh) 用於用作prmt5抑制剂的取代核苷类似物
BR122021004452B1 (pt) Compostos análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico e composição farmaceutica e uso como inibidores de prmt5

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200929

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220704

R150 Certificate of patent or registration of utility model

Ref document number: 7101171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250